NICE Backs Eylea After Securing Patient Access Scheme From Bayer
This article was originally published in The Pink Sheet Daily
Executive Summary
Blockbuster seller Eylea gains momentum with the U.K. health technology assessment agency its use for treating diabetic macular edema after the injectable’s local vendor Bayer grants the National Health Service an undisclosed price discount.